Welcome to LookChem.com Sign In|Join Free
  • or
Cyclopropanesulfonamide, 1-propyl- (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

681808-58-2

Post Buying Request

681808-58-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

681808-58-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 681808-58-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,1,8,0 and 8 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 681808-58:
(8*6)+(7*8)+(6*1)+(5*8)+(4*0)+(3*8)+(2*5)+(1*8)=192
192 % 10 = 2
So 681808-58-2 is a valid CAS Registry Number.

681808-58-2Downstream Products

681808-58-2Relevant academic research and scientific papers

7-AZADISPIRO [3.0.4.1] DECANE-8-CARBOXAMIDES AS HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 55, (2010/11/03)

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

-

Page/Page column 214, (2009/01/20)

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Hepatitis C Virus Inhibitors

-

Page/Page column 24, (2008/12/05)

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

-

Page/Page column 26, (2008/06/13)

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.

Substituted cycloalkyl P1' hepatitis C virus inhibitors

-

Page/Page column 42, (2010/02/06)

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 681808-58-2